Although many preventive measures have been taken, the incidence of hepatitis C (hepatitis C) virus infection after hemodialysis (hemodialysis) is still significantly higher than that of the general population. Patients with renal insufficiency are infected with hepatitis C virus, which undoubtedly adds to the problem. On top of renal insufficiency, the liver, the largest metabolic organ of human body, is invaded by hepatitis C virus, resulting in damage to liver function, which may in turn aggravate renal failure in serious cases. In addition, the “misfortune is not the same” will certainly increase the psychological burden of patients and even pessimism. Therefore, aggressive treatment of hepatitis C may be more necessary and urgent for them than for general patients. Currently, interferon plus ribavirin combination therapy is the most effective method to fight against hepatitis C virus. However, the treatment of post-hemodialysis hepatitis C infection in patients with renal insufficiency is clearly not equivalent to that of general hepatitis C patients and must be more prudent, more cautious, and more individualized. There are generally two states of post-hemodialysis hepatitis C, and the treatment differs: some patients with hepatitis C virus infection can maintain normal liver function, and no clinical manifestations of chronic hepatitis, these patients can generally be suspended from antiviral therapy, but must be regularly tested and followed up. The other situation is that the patient has developed hepatitis symptoms, liver function abnormalities (especially transaminase elevation), indicating that hepatitis has been active, should be considered for antiviral treatment, the drug can also choose interferon, but because of the patient’s renal insufficiency, interferon is easy to accumulate in the body and lead to a significant increase in its side effects, most patients may therefore have to discontinue treatment, for this reason, the use of interferon in patients with renal insufficiency must The first thing you need to do is to start with a small dose and gradually increase it to the maximum tolerable amount, while extending the time between doses and extending the total course of treatment, so that the side effects of interferon can be reduced to a minimum and the best therapeutic effect can be obtained. Ribavirin is generally not used in hemodialysis patients because the drug has the side effect of possibly damaging human red blood cells, and hemodialysis patients often have varying degrees of anemia. In some special cases, such as those with poor results with interferon alone, no anemia or very mild anemia, or on the basis of erythropoietic drugs, the combination of ribavirin can be considered, but the relevant indicators must be closely monitored to avoid serious anemia and other adverse consequences. Indeed, it is unfortunate that patients with renal insufficiency are infected with hepatitis C after hemodialysis, but fortunately, the effect of interferon therapy in these patients is better than that of general hepatitis C. This may be due to the longer retention time of interferon in the body of patients with renal insufficiency and the longer duration of action of the drug on the virus.